Abstract
Laboratory measurements
Total cholesterol (TCH, mmol/L), triglyceride (TG, mmol/L), fasting blood glucose (FBG, mmol/L), creatinine (CR, µmol/L), fasting high-density lipoprotein cholesterol(HDL-C, mmol/L), fasting low-density lipoprotein cholesterol (LDL-C, mmol/L), apolipoprotein A (apoA, g/L), and apolipoprotein B (apoB, g/L) levels were determined using enzymatic procedures on an automated Hitachi 7600 auto-analyser (Hitachi Co., Tokyo, Japan).
Measurement of human plasma lipoprotein-associated phospholipase A2
All samples (5 ml) were collected in EDTA plasma tubes on the morning after arrival before any medical or interventional therapy was performed. The samples were processed within 4 hours and stored at 4°C. Plasma was collected after centrifugation (15 min at 1000g) and was stored at -80°Cuntil further analysis. The amount of Lp-PLA2 was measured with a commercially available turbidimetric immunoassay (TIA) (Norman Inc, Nanjing, Jiangsu, China) after thawing plasma aliquots at 4°C. All the assays were performed by the Nanjing Norman Biological Technology Co., Ltd, Nanjing 210031, Jiangsu Province, China. The amount of Lp-PLA2 was measured using a commercially available TIA (Lp-PLA2 TestKit, Norman cat no 14082101) with a Norman Turbidimeter (NORMAN-2).The manufacturer's instructions for thawing samples were strictly followed. In samples with a measured concentration exceeding 800 ng/ml, the presence of interfering heterophilic antibodies was checked for, and samples in which they were found to be present were excluded. Intra-and inter-assay coefficients of variation were 1.2% and 2.6%, respectively, based on the EP5 protocol (Evaluation of Precision Performance of Quantitative Measurement Methods) and using Quality Control Table 1 . Baseline characteristics of the subjects grouped according to ethnicity. SBP, systolic blood pressure; DBP, diastolic blood pressure; CR, creatinine; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CHD, coronary heart disease; Lp-PLA2 (ng/ml), lipoprotein-associated phospholipase A2. Due to the significant differences in ages across the different ethnicities, an analysis of covariance (ANCOVA) was performed with the variable age as a covariate, and significant differences in Lp-PLA2 concentrations across the various ethnicities were evident (p=0.000) Serum at concentrations of 190 and 280 ng/ml. In 100 healthy subjects, the Lp-PLA2 concentration ranged from 100 to 295 ng/mL. Control values were specifically obtained from 100 healthy Chinese volunteers (52%men), who had a mean age of 25±5 years (range: 20 to 30 years), had no cardiovascular risk factors (e.g., diabetes, smoking, hypertension, and dyslipidemia) and had not undergone any treatments. In healthy controls, the mean Lp-PLA2 concentration was 126 ± 37 ng/ml.
Cigarette smoking and alcohol intake
Cigarette smoking and alcohol intake were assessed using a standardized questionnaire. Subjects were divided into nonsmokers (had never smoked cigarettes regularly); former smokers (had stopped smoking before this study); and persistent smokers. And, the subjects' smoking status was classified as either "never smoking" or "smoking". The former referred to those who never smoked, and the latter group included both former and current smokers [20, 21] . Subjects who reported consuming at least 50 g/week of alcohol were considered current drinkers. Alcohol intake status was classified as either "never drinking" or "drinking" (including both former and current drinkers) [22] .
Coronary angiography
Coronary arteries were cannulated using either the Judkins technique [23] or through a radial approach with 6F catheters, and data were recorded at a rate of 30 frames/s. Significant CHD was defined as at least one major epicardial vessel with >50% stenosis, and controls were defined as all of the major epicardial vessels with<50% stenosis [24] . The severity of coronary atherosclerosis was defined based on the Gensini scoring system [25] .
Statistical analyses
The data were analysed using the Statistics Package for Social Sciences (ver. 16.0; SPSS Incorporated, Chicago, IL, USA).Patients were classified into four groups according to the Lp-PLA2 concentrations using quartile values as the cut-off points; therefore, each group had a similar number of patients, minimizing any bias that may have been produced in the statistical analyses. Data for age, systolic blood pressure (SBP, mmHg), diastolic blood pressure (DBP, mmHg), and TCH, TG, FBG, HDL-C,LDL-C, apoA, apoB, and Lp-PLA2 levels were skewed, and are presented as median values and quartile ranges. Comparisons were analysed using Kruskal-Wallis H tests. Categorical variables, including sex, smoking status, drinking status, and CHD status, were compared among the groups of patients using chi-squared analyses. Spearman two-way tests were used to assess the relationships between two quantitative variables, and we evaluated independent predictors of Lp-PLA2 utilizing univariate and multiple logistic regression analyses. A receiver operator curve (ROC) analysis was also conducted to examine whether Lp-PLA2 and traditional risk factors can be used to predict CHD [26] . Significance was assumed if the null hypothesis could be rejected with >95% confidence. All p-values are two-tailed.
To further explore the synergistic effect of Lp-PLA2 and classical risk factors on the risk of CHD, a 4×2 table approach was conducted to calculate odds ratios (ORs), 95% confidence intervals (CIs) and twotailed p-values, and multiple indexes (SI, SIM, RERI, and AP, as defined in the equations below) were used to evaluate the synergistic effect between Lp-PLA2 and classical risk factors. It was assumed that subjects unexposed to the traditional risk factors and with an Lp-PLA2 concentration below the cut-off value have a certain background risk for CHD (defined as OR00, with the value assumed to be 1).OR01 refers to the relative risk for CHD among those unexposed to a risk factor with an Lp-PLA2 value above the cut-off value when compared with those with neither an Lp-PLA2 value above the cut-off nor exposure to risk factors. Similarly, OR10 refers to the relative risk for CHD among those with a Lp-PLA2 concentration below the cut-off value but with exposure to an environmental risk factor when compared with those with neither an Lp-PLA2 concentration above the cut-off value nor exposure to risk factors.OR11 is the ratio of the CHD risk among subjects exposed to risk factors with an Lp-PLA2 concentration above the cut-off value when compared with the CHD risk among unexposed subjects with an Lp-PLA2 concentration below the cut-off value. These ORs were used in the calculation of the synergy indexes (SIs), such that SI=(OR11-1)/(OR10+OR01-2) and SIM=OR11/(OR10×OR01); the relative excess risk due to interaction, RERI=OR11-OR10-OR01+1;and the attributable proportion of the disease due to interaction, AP=RERI/OR11 [27, 28] .
Results

Baseline characteristics of the subjects grouped according to ethnicity
The baseline characteristics of the subjects grouped according to ethnicity are presented in Table 1 . Significant differences in age (p=0.033), Gensini scores (p=0.000), and LDL-C (p=0.002), apoA (p=0.002), apoB (p=0.023), and Lp-PLA2 (p=0.005) concentrations ( Fig.  1) were observed across the various ethnicities. Furthermore, the frequency distribution for CHD status (p=0.012) differed significantly across the various ethnicities. Due to the significant difference in age across the ethnicities, an analysis of covariance (ANCOVA) was performed, with age as a covariate, and significant differences in Lp-PLA2 concentrations across the various ethnicities were evident (p=0.000).
Demographic, clinical and biochemical characteristics of patients according to Lp-PLA2 concentrations
Lp-PLA2 concentrations in the subjects in the present study ranged from99.0 ng/ml to 414.21 ng/ml, with a median of 192.24 ng/ml (quartile range, 127.27-267.26 ng/ml). Table  2 shows the demographic, clinical and biochemical characteristics of patients according to Lp-PLA2 concentrations, with quartile values used as cut-off points. The results suggest that Table 2 . Age, clinical and biochemical characteristics in patients grouped according to Lp-PLA2 concentration using quartile values as cut-off points. SBP, systolic blood pressure; DBP, diastolic blood pressure; CR, creatinine; HDL-C, high-density lipoprotein cholesterol;LDL-C, low-density lipoprotein cholesterol; CHD, coronary heart disease; Lp-PLA2, lipoprotein-associated phospholipase A2 different distributions for age (p=0.003), TGs (p=0.001), apoA concentrations (p=0.010), and Gensini scores (p=0.000) were observed across the various groups, and the frequency distribution for CHD status (p=0.000) was significantly different across the groups. Table 3 shows the results of the Spearman correlation analysis between Lp-PLA2 concentration, age and clinical and biochemical characteristics. Spearman correlation analyses indicated that Lp-PLA2 concentration was positively associated with age (r=0.121, p=0.000), Gensini score (r=0.176, p=0.000), LDL-C (r=0.067, p=0.044),and apoB (r=0.067, p=0.043) concentrations (Fig. 2) , and Lp-PLA2 concentration was negatively associated with apoA (r=-0.092, p=0.005) concentration. Table 4 . Receiver operating characteristic curve analyses for subjects with CHD and controls. CI, confidence interval; AUC, area under the receiver operating characteristic curve; SBP, systolic blood pressure; DBP, diastolic blood pressure; CR, creatinine; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CHD, coronary heart disease; Lp-PLA2, lipoprotein-associated phospholipase A2. AUC< 0.5 indicates the levels in patients with CHD lower than that of controls, AUC> 0.5 indicates the levels in patients with CHD higher than that of controls Table 5 . The optimal cut-off and Youden index values for Lp-PLA 2 and traditional risk factors. SBP, systolic blood pressure; DBP, diastolic blood pressure; CR, creatinine; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CHD, coronary heart disease; Lp-PLA2, lipoprotein-associated phospholipase A2 Fig. 3 . The receiver operating characteristic curve for the ability of Lp-PLA2 to differentiate CHD patients from control individuals. 
Spearman correlations between Lp-PLA2 concentration, age and clinical and biochemical characteristics
Receiver operating characteristic curve analyses in subjects with CHD and controls.
To further explore the applicability of Lp-PLA2and classical risk factors as potential diagnostic biomarkers of CHD, ROC analyses were performed, and the results are shown in Table 4 . The area under the receiver operating characteristic curve(AUC) was 0.589 for Lp-PLA2 (95%CI: 0.549-0.629, p=0.000) (Fig. 3) , 0.590 for age (95%CI: 0.550-0.629, p=0.000) (Fig. 4) , 0.590 for SBP (95%CI: 0.551-0.629, p=0.000) (Fig. 5) , 0.551 for DBP (95%CI: 0.511-0.591, p=0.014) (Fig. 6) , 0.610 for FBG(95%CI: 0.572-0.648, p=0.000) (Fig. 7) , 0.559 for CR (95%CI: 0.518-0.599, p=0.005) (Fig. 8) , 0.451 for HDL-C (95%CI: 0.411-0.491, p=0.018) (Fig.  9) , and 0.456 for apoA (95%CI: 0.416-0.496, p=0.032) (Fig. 10) . The optimal cut-off value, the sensitivity, the specificity and the Youden index values of the variables are expressed in Table 5 .
Univariate logistic regression analysis of characteristics between the CHD and non-CHD groups
The results of the univariate logistic regression analysis of the variables between the CHD and control groups are shown in Table 6 . Compared with the subjects less than 59.5 years old, subjects over 59.5 years old exhibited a75% increase in the risk for CHD (OR, 1.750; Table 6 . Univariate logistic regression for the presence of obstructive CHD. CHD, coronary heart disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; CR, creatinine; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp-PLA2, lipoprotein-associated phospholipase A2 Fig. 9 . The receiver operating characteristic curve for the ability of HDL-C to differentiate CHD patients from control individuals. 95% CI, 1.319-2.323, p=0.000) for all subjects and a 108.4% increase (OR, 2.084; 95%CI, 1.466-2.963, p=0.000) for male subjects; however, for female subjects, a significant difference was not found. Compared with female subjects, male subjects showed a 93.5% increased risk for CHD (OR, 1.935; 95%CI, 1.427-2.625, p=0.000). In addition, smokers were 33.4% more likely to suffer from CHD (OR, 1.334; 95% CI, 1.004-1.772, p=0.047) than non-smokers. Moreover, the risk for CHD increased with increasing SBP, FBG, and LDL-C in all the subjects and in the subpopulations grouped by sex. Moreover, a significant risk for CHD with respect to TG levels was found for all subjects and for female subjects. Compared with subjects with an Lp-PLA2 concentration below 142.03 ng/ml, subjects with an Lp-PLA2 concentration above 142.03 ng/ml were 118.5% more likely to suffer from CHD (OR, 2.185; 95% CI, 1.625-2.938, p=0.000) for the entire population, were 95.5% more likely to suffer from CHD (OR, 1.955; 95% CI, 1.364-2.801, p=0.000) for male subjects and were 191.2% more likely to suffer from CHD (OR, 2.912; 95% CI, 1.679-5.050, p=0.000) for female subjects.
The multivariate logistic regression analysis of characteristics between the CHD and non-CHD groups
A multivariate logistic regression (Forward: Conditional method) was used to identify risk factors for CHD for the entire population. In the multivariate model for the whole population, we included the following variables: age, sex, smoking status, drinking status, SBP, DBP, and TCH, TG, FBG, HDL-C, LDL-C, apoA, apoB, and Lp-PLA2 concentrations. The results are reported in Table 7 Table 8 . Synergistic effect of Lp-PLA2 and classical risk factors in CHD patients and controls. CHD, coronary heart disease; SBP, systolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FBG, fasting blood glucose; Lp-PLA2, lipoprotein-associated phospholipase A2 Table 9 . The indexes of the synergistic effect between Lp-PLA2 and classical risk factors. SI, Rothman's synergy index for an interaction; SIM, Khoury's synergy index for an interaction; RERI, relative excess risk due to an interaction; AP, proportion of disease attributable to an interaction; CHD, coronary heart disease; SBP, systolic blood pressure; HDL-C, highdensity lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FBG, fasting blood glucose; Lp-PLA2, lipoprotein-associated phospholipase A2
Interaction between Lp-PLA2 and classical risk factors
The analysis of the possible positive/negative associations between Lp-PLA2 and classical risk factors is expressed in Tables 8 and 9 . According to the results of the ROC analysis, the Lp-PLA2 cut-off level of 142.03 ng/ml was the optimal value; thus, subjects with an Lp-PLA2 concentration above 142.03 ng/ml were considered to have an elevated risk of CHD. Regarding the baseline risk for subjects unexposed to classical risk factors or to an Lp-PLA2-associated risk (reference category, 1.0), the OR estimating the joint effect of sex (male was defined as the sex at greater risk) and FBG was significantly higher than the ORs estimating the effects of each factor in the absence of the other. A positive association between Lp-PLA2 concentration and age was found (SI=20.95, SIM=2.89, and AP=0.64), and in these groups, the proportion of CHD attributable to the interaction between Lp-PLA2 and age was as high as 64%. The same analysis regarding sex found significant results for subjects with risk-associated Lp-PLA2 levels in males (SI=1.15, SIM=0.67, and AP=0.10). Risk-associated Lp-PLA2 levels interacted with SBP in predicting CHD (SI=2.45, SIM=1.56, and AP=0. 45 ). An interaction was found between HDL-C (thus, subjects with an HDL-C concentration less than 1.36 mmol/l were considered to be at risk) and Lp-PLA2 concentrations (SI=1.22, SIM=0.92, and AP=0.13).LDL-C and Lp-PLA2 levels interacted significantly in predicting the onset of CHD, and this combination accounted for 62% of the CHD cases (SI=3.47, SIM=2.00, and AP=0.62). Risk-associated Lp-PLA2 levels positively reinforced the risk associated with FBG (SI=2.27, SIM=1.37, AP=0.47).
Discussion
The main findings from this hospital-based multi-ethnic study of adult Chinese patients are as follows: 1) a significant difference in Lp-PLA2 concentrations was observed across the various ethnicities, 2) Lp-PLA2 concentrations were positively associated with age and the severity of the coronary atherosclerosis as estimated based on Gensini scores, 3) Lp-PLA2 concentrations were found to be independently associated with the risk of CHD, and 4) a positive interaction existed between Lp-PLA2 concentrations and classical risk factors. To the best of our knowledge, this is the first multi-ethnic study to explore the interactions between Lp-PLA2 and classical risk factors affecting the risk of CHD.
Lp-PLA2, also known as platelet activating factor 2 acetyl hydrolase (PAF2AH), is an enzyme capable of hydrolysing the lipoprotein and two acyl ester bonds on cell membrane phospholipids and glycerine to form non-esterified fatty acids (NEFAs) and lysophospholipids. This enzyme is secreted by inflammatory cells, such as monocytes, macrophages, T-lymphocytes, and mast cells, which exist in large amounts in atherosclerotic plaques [29] . In human plasma, approximately 80% of Lp-PLA2 is bound to low-density lipoproteins (LDLs), while 15%-20% is bound to high-density lipoproteins (HDLs) [16] . Lp-PLA2 plays a role in the progression of atherosclerosis because it has both pro-inflammatory and anti-inflammatory functions. The ability of Lp-PLA 2 to decompose LDL indicates that it has anti-atherosclerosis properties, but NEFAs and lysophosphatidylcholine (LPC), which are products of the Lp-PLA 2 -catalysed hydrolysis of LDL and have strong pro-inflammatory effects, can stimulate the generation of adhesion molecules and cytokines, resulting in mononuclear cell accumulation from the lumen into the intima [30] . Accumulating evidence suggests that Lp-PLA2 levels are closely related to the occurrence and development of atherosclerotic diseases. A systematic review of the literature including 33 studies found 30 that showed a significant association between Lp-PLA2 concentrations and cardiovascular events [31] . Additionally, a meta-analysis using individual records from 79,036 participants in 32 prospective studies (yielding 17,722 incidences of fatal or non-fatal outcomes during 474,976 person-years for subjects at risk) indicated that Lp-PLA2 activity and concentration each show continuous associations with the risk of CHD [16] . Lp-PLA2 is not only involved in the entire process of atherosclerosis but also promotes the malignant development of plaques [30] . Liu et al. demonstrated that plasma Lp-PLA 2 activity is associated with plaque rupture in patients with CAD, independent of traditional CAD risk factors, such as hs-CRP levels and intravascular ultrasound (IVUS) parameters [32] . Therefore, Lp-PLA2 may be a useful therapeutic target to assess in trials studying CHD prevention.
However, some studies have found no evidence of a relationship between Lp-PLA2 levels and other risk factors in the development of CHD. Clinical research on acute coronary syndrome (ACS) patients has shown that these patients had higher Lp-PLA2 levels than healthy controls, but Lp-PLA2 levels were not related to the risk of future cardiovascular events or mortality. They were significantly correlated with lipid levels but were only weakly correlated or were unrelated to other well-established risk markers [33] . Lp-PLA2 concentrations were not associated with coronary or carotid subclinical atherosclerosis in retired National Football League players in the United States [34] .Elevated Lp-PLA2 levels are associated with an increased risk of coronary events. A double-blind trial randomly assigned 15,828 patients with a stable CHD to receive once-daily darapladib (at a dose of 160 mg), a selective oral inhibitor of Lp-PLA2, or a placebo. The results indicated that in patients with stable CHD, darapladib did not significantly reduce the risk of the primary composite end point of cardiovascular death, myocardial infarction, or stroke [35] . Mayer et al. speculated that treatment with darapladib might be more suitable in primary than in secondary prevention [36] . Several studies have also provided a genetic explanation, indicating that Lp-PLA2 may serve as a biomarker that is affiliated only with lipoprotein metabolism, vascular inflammation, and plaque vulnerability, reflecting another pathophysiological mechanism instead of a causal pathway leading to CVD [37] [38] [39] .We believe that some underlying mechanisms may explain these discrepancies. First, the protocols of these studies were quite different. The subjects enrolled in the previous studies had different ethnicities, ages, and sexes, and the results in our current multi-ethnic study indicate that the level of Lp-PLA2 significantly differs across various ethnic groups, even after adjusting for age. Second, the end-points of these studies are quite different. Third, all of the previous studies focused only on the association between Lp-PLA2 and cardiovascular disease, and the interaction of Lp-PLA2 with traditional risk factors was not explored, which may explain the discrepancies. Positive interactions between Lp-PLA2 and classical risk factors were found in the present study. In the present study, we found that plasma Lp-PLA2 concentration was positively associated with age, and LDL-C, and apoB concentrations and negatively associated with apoA concentrations. This result is partially consistent with the findings of previous studies [40, 41] . Some studies found that Lp-PLA2 levels correlated positively with TC but correlated negatively with HDL-C levels [40] [41] [42] . However, we did not observe such correlations in the present study. Previous studies have demonstrated that Lp-PLA2 activity is an independent predictor of CHD after adjusting for traditional risk factors of CVD [37, 43, 44] . To further explore the relationship between the Lp-PLA2 concentration and CHD, a univariate analysis was performed, and the results showed that Lp-PLA2 concentration appeared to be a predictor of CHD. After adjusting for other risk factors, Lp-PLA2 concentration remained a potential independent predictor of CHD. The multivariate logistic regression also indicated that variables such as age, sex, SBP, and non-HDL-C, LDL-C, and FBG levels remain independently related to the development of CHD.
The current study was unique in that the enrolled subjects were not limited to the Han ethnicity but also included the Uygur, Kazakh, Hui and other ethnicities. A somewhat surprising finding was the significant differences across ethnic groups. The results show that the average serum concentration of Lp-PLA2 was highest in the Uygur population, while the Han population showed the lowest concentration. Coronary artery calcification, the noninvasive imaging of atherosclerosis, provides a useful tool to assess coronary atherosclerosis burden. Previous studies demonstrated that the independent association of Lp-PLA2 mass with calcified coronary plaque existed in young adults, and, Lp-PLA2 mass may be a potential biomarker of subclinical cardiovascular risk [45, 46] . However, multiethnic study regard as the relationship between Lp-PLA2 mass and the increased CHD risk in individuals with and without subclinical disease defined by the presence of calcified coronary artery have not been reported. Therefore, the related study will be carried out in the future.
The complex aetiology of CHD and the multiple environmental factors that are involved are typically not evaluated together. Lp-PLA2is a 50-kDa lipase with inflammatory and atherogenic actions and has been shown to be an independent predictor of the development of CHD [47] .Within the vessel walls, the interaction between oxidatively modified LDL and Lp-PLA2 generates oxidized fattyacids (OxFAs) and LPC, which are powerful inflammatory and atherogenic factors [48] . We performed additional analyses to determine whether the simultaneous presence of increased Lp-PLA2 levels and well-established risk factors could enhance CHD onset. The results were interesting, particularly the results of the subgroup analysis. The proportion of CHD attributable to an interaction between increased age and increased Lp-PLA2 levels was 64% for the present population, and the Rothman's synergy index for the interaction increased to 20.95. This effect was also found when considering LDL-C and FBG levels and SBP as traditional risk factors (SI=3. 47 13) . Although a synergistic effect of Lp-PLA2 and classical risk factors on the risk of CHD has been confirmed, the mechanism underlying the interaction is unknown. The present study suggests that lowering Lp-PLA2 levels and controlling for the synergistic effects would reduce the risk of CHD and improve the outcomes of subjects with CHD.
Circulating lipoprotein-associated phospholipase A2 can be measured by different assays ascertaining Lp-PLA2 mass or Lp-PLA2 activity. Many literatures showed that Lp-PLA2 activity, not only mass, was associated with increased risk for a cardiovascular disease event [49] . However, there is only moderate correlation between Lp-PLA2 mass and Lp-PLA2 activity (r=0.51) [16] , and the independent role of these two measures in cardiovascular disease is unknown. Other study confirms that Lp-PLA2 mass but not its activity was independently associated with calcified coronary plaque among young adults [46] . Familial factors explain about one-half and one-quarter of the variance in Lp-PLA2 activity and mass, respectively [50, 51] , and Meta-analysis of GWAS from five populationbased studies comprising 13 664 subjects suggests that genes influencing Lp-PLA2 mass and Lp-PLA2 activity differ [52] . Therefore, additional studies are warranted to elucidate the mechanism underlying the association of Lp-PLA2 mass and activity with increased risk for a cardiovascular disease event.
Limitations
We are aware that this study has some potential limitations. The medication records of the subjects have not been indicated in the present study. Since Lp-PLA2 is considered a marker of vascular inflammation, which might be decreased by some medication (e.g., statin use) [53] [54] [55] , the effect of statin and other medications therapy on lipoprotein associated phospholipase A2 levels will be conducted in the multi-ethic population in the future. Furthermore, we did not determine Lp-PLA2 activity; thus, the interaction between plasma Lp-PLA2 activity and classical risk factors remains uncertain; however, previous studies have shown a strong correlation between Lp-PLA2 concentration and activity [16, 56] . Therefore, we propose the novel hypothesis that the synergism of Lp-PLA2 activity with classical risk factors in the risk of CHD may be significant. Finally, because our study was cross-sectional in design, we are unable to infer any definite cause-effect relationships.
Conclusion
In summary, the results of the present study suggest that increased plasma levels of Lp-PLA2 at baseline are associated with an increased risk of CHD; thus, measuring Lp-PLA2 levels may be an expedient method of identifying subjects who are at a high risk for CHD. The
